|
BKNM-DP-170
N/A |
|
DPPE-PEG-CDI ¶þÓ²Ö¬õ£»ùÁ×Ö¬õ£ÒÒ´¼°·-¾ÛÒÒ¶þ´¼-N,N-̼õ£¶þßäßò
|
£¤Member visible
|
|
|
BKNM-DP-169
N/A |
|
DSPE-PEG-antagonist Gµ°°×¾ÛÒÒ¶þ´¼Á×Ö¬
|
£¤Member visible
|
|
|
BKNM-DP-168
N/A |
|
DSPE-PEG-FPBA ¶þÓ²Ö¬õ£»ùÁ×Ö¬õ£ÒÒ´¼°·-¾ÛÒÒ¶þ´¼-3-ôÈ»ù-4-·ú±½ÅðËá
|
£¤Member visible
|
|
|
BKNM-DP-167
N/A |
|
DSPE-PEG-HC ¶þÓ²Ö¬õ£»ùÁ×Ö¬õ£ÒÒ´¼°·-¾ÛÒÒ¶þ´¼-7-ôÇ»ùÏ㶹ËØ
|
£¤Member visible
|
|
|
BKNM-DP-165
N/A |
|
DSPE-hyd-PEG-AA PHÃô¸ÐÐÍÖ¬ÖÊÌå
|
£¤Member visible
|
|
|
BKNM-DP-164
N/A |
|
DSPE-PEG-Nitrobenzofurazan Á×Ö¬-¾ÛÒÒ¶þ´¼-Ïõ»ù±½²¢ß»à«
|
£¤Member visible
|
|
|
BKNM-DP-163
N/A |
|
DSPE-PEG-IA Á×Ö¬-¾ÛÒÒ¶þ´¼-µâÒÒõ£°·
|
£¤Member visible
|
|
|
BKNM-DP-162
N/A |
|
DSPE-PEG-Alexa Fluor Á×Ö¬-¾ÛÒÒ¶þ´¼-AlexaFluorÓ«¹âȾÁÏ
|
£¤Member visible
|
|
|
BKNM-DP-161
N/A |
|
Trastuzumab-PEG-DSPE ÇúÍ×Öéµ¥¿¹-¾ÛÒÒ¶þ´¼-¶þÓ²Ö¬õ£»ùÁ×Ö¬õ£ÒÒ´¼°·
|
£¤Member visible
|
|
|
BKNM-DP-160
N/A |
|
DSPE-PEG-SWCNTs Á×Ö¬¾ÛÒÒ¶þ´¼Ì¼ÄÉÃ×¹Ü
|
£¤Member visible
|
|
|
BKNM-DP-159
N/A |
|
DSPE-PEG-SP2-AA¶þÓ²Ö¬õ£»ùÁ×Ö¬õ£ÒÒ´¼°·-¾ÛÒÒ¶þ´¼-SP2-AA
|
£¤Member visible
|
|
|
BKNM-DP-158
N/A |
|
DSPE-PEG 2000-TM Á×Ö¬¾ÛÒÒ¶þ´¼-Ѫ˨µ÷½Úµ°°×
|
£¤Member visible
|
|
|
BKNM-DP-157
N/A |
|
anti-HER2 scFv-PEG-DSPE µ¥Á´¿¹ÌåÖ¬ÖÊÌåÖƱ¸
|
£¤Member visible
|
|
|
BKNM-DP-157
N/A |
|
anti-HER2 scFv-PEG-DSPE µ¥Á´¿¹ÌåÖ¬ÖÊÌåÖƱ¸
|
£¤Member visible
|
|
|
BKNM-DP-156
N/A |
|
SPE-PEG-SG¶þÓ²Ö¬õ£»ùÁ×Ö¬õ£ÒÒ´¼°·-¾ÛÒÒ¶þ´¼-SG
|
£¤Member visible
|
|
|
BKNM-DP-155
N/A |
|
DSPE-PEG-Thrombomodulin¶þÓ²Ö¬õ£»ùÁ×Ö¬õ£ÒÒ´¼°·-¾ÛÒÒ¶þ´¼-¿¹Ìå
|
£¤Member visible
|
|
|
BKNM-DP-154
N/A |
|
DSPE-PEG-OVA¶þÓ²Ö¬õ£»ùÁ×Ö¬õ£ÒÒ´¼°·-¾ÛÒÒ¶þ´¼-ova
|
£¤Member visible
|
|
|
BKNM-DP-153
N/A |
|
DSPE-PEG2000-PSP¶þÓ²Ö¬õ£»ùÁ×Ö¬õ£ÒÒ´¼°·-¾ÛÒÒ¶þ´¼-PSP
|
£¤Member visible
|
|
|
BKNM-DP-152
N/A |
|
DSPE-PEG-Riboflavin¶þÓ²Ö¬õ£»ùÁ×Ö¬õ£ÒÒ´¼°·-¾ÛÒÒ¶þ´¼-ºË»ÆËØ
|
£¤Member visible
|
|
|
BKNM-DP-152
N/A |
|
DSPE-PEG-Riboflavin¶þÓ²Ö¬õ£»ùÁ×Ö¬õ£ÒÒ´¼°·-¾ÛÒÒ¶þ´¼-ºË»ÆËØ
|
£¤Member visible
|
